Researchers have identified the protein mechanism that senses bicarbonate fluctuations and adjusts blood pH levels.. A Canadian/U.S. research team led by University of Alberta biological sciences professor, Greg Goss and his graduate students Martin Tresguerres and Scott Parks achieved the first demonstration of the process in a whole animal. The researchers found that the protein adenylyl cyclase sensed and then regulated the pH blood levels in a dogfish shark following feeding. "Researchers have been trying to see how this process works for 50 years, " said Goss. "It opens a whole avenue of possibilities of how we could regulate the blood pH in the human body.
MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, reported today in vivo data for bladder and liver cancer demonstrating further advancement of the Company's oncology programs. The Company reported a reduction in tumor growth in both liver and bladder cancers by targeting genes key to tumor progression, via both systemic and local delivery with the Company's proprietary UsiRNAs delivered by its novel DiLA2 platform. In addition, MDRNA disclosed the establishment of an early collaborative effort with a major international pharmaceutical company, its second such effort. In a presentation at the 2010 OneMedForum in San Francisco, Mr.
Patients with advanced chronic kidney disease (CKD) often do not receive adequate end-of-life care and are unhappy with the medical decisions made as their conditions worsen, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that end-of-life care should be improved to meet the needs of CKD patients. Although many CKD patients die prematurely, surprisingly little research has been done to study CKD patients' preferences for end-of-life care and how those preferences align with the care they receive. Sara Davison, MD, FRCP(C) (University of Alberta, Canada) surveyed 584 late stage CKD patients as they came to dialysis, transplant, or pre-dialysis clinics in a Canadian, university-based kidney program between January and April 2008.
Researchers from the US and Sweden have for the first time identified a gene variant that is linked with aggressive prostate cancer, adding weight to the idea that patients' genetic information will one day help decide treatment decisions. The study was published online before print in the Proceedings of the National Academy of Sciences, PNAS, and is the work of lead author Dr Jianfeng Xu, professor of epidemiology and cancer biology at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, US and colleagues, including some based at other research establisments in the US and Sweden. The authors wrote that prostate cancer accounts for a quarter of all cancers diagnosed in the US, and although most men who develop it have the slow-growing form, aggressive prostate cancer is the second leading cause of cancer death among male Americans, with over 27, 000 dying every year from the disease.
Spectrum Pharmaceuticals Completes Enrollment In Second Of Two Phase 3 Pivotal Trials For Apaziquone In Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals. "We are delighted to have achieved our enrollment objectives in both clinical trials on target, " said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. "Currently, there are no FDA approved drugs for immediate instillation following trans-urethral resection of bladder tumor (TUR-BT).
Raptor Pharmaceutical Corp. Announces Publication Of Results From Phase 2a Trial Of DR Cysteamine For Treatment Of Cystinosis
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The Phase 2a study demonstrated proof-of-concept for DR Cysteamine, which is Raptor's proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule. Immediate-release cysteamine bitartrate ("IR Cysteamine") is the current standard of care for treating cystinosis. The results indicated that when given twice daily, the prototype DR Cysteamine formulation was effective at maintaining low white blood cell ("WBC") cystine levels (<2 nmol half-cystine/mg protein) in subjects with cystinosis.